News & Events zu Atara Biotherapeutics, Inc. (ATRA)ATRAAtara Biotherapeutics, Inc.

Atara Reports Q2 Revenue of $600K, Exceeds Expectations

Reports Q2 revenue $600K, consensus $366.67K. As previously communicated, PFP has indicated they intend to submit an updated dataset with additional patients and longer follow-up from the pivotal Phase 3 single arm ALLELE study as well as supportive data. Atara anticipates providing a further regulatory update later this quarter. Under its commercialization agreement with Pierre Fabre Laboratories, Atara is eligible to receive a $31M milestone payment upon FDA approval of the tabelecleucel BLA, as well as significant double-digit tiered royalties as a percentage of net sales, and milestones related to commercial sales of EBVALLO.

Atara Expects Significant Decline in Operating Expenses into Mid-2027

Operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and first half of 2026. Atara expects its cash, cash equivalents, and short-term investments as of June 30, 2026, combined with operating efficiencies achieved in 2025 and first half of 2026, will be sufficient to fund planned operations into mid-2027.

Atara Reports Cash and Short-Term Investments Totaling $8.4M

Reports cash, cash equivalents and short-term investments as of March 31 totaled $8.4M as compared to $8.5M as of December 31, 2025. The company said, "As previously communicated, Pierre Fabre Pharmaceuticals (PFP), with Atara's support, had a productive meeting with the FDA and discussed a potential path forward to resubmitting the tab-cel Biologics License Application (BLA). The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a marketing application of tab-cel for the proposed indication. PFP has indicated they intend to submit an updated dataset with additional patients and longer follow-up from the pivotal Phase 3 single arm ALLELE study as well as supportive data, as a part of the resubmission plan being defined with the FDA. Atara anticipates providing a further regulatory update in the third quarter."Atara said its operating expenses are "expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025."